- (PLX AI) - Genmab shares rose 2.7% after Nordea raised its price target on the stock to DKK 3,304 from DKK 3,191 and reiterated a buy recommendation.
- • Genmab has good risk/reward for arbitration in its Johnson & Johnson dispute at the current stock price, Nordea said
- • The biotech company has stellar fundamentals and a strongly growing top line, Nordea said
- • Genmab's rich pipeline is likely to deliver several triggers this year, the analysts said
- • Meanwhile, a peak sales forecast of $12.5 billion for DArzalex/Faspro may be conservative, Nordea said